What is the recommended treatment for oral lichen planus?

Treatment of Oral Lichen Planus

First-Line Treatment: Topical High-Potency Corticosteroids

Topical corticosteroids are the recommended first-line treatment for oral lichen planus, with betamethasone sodium phosphate 0.5 mg dissolved in 10 mL water used as a rinse-and-spit preparation 1-4 times daily being the cornerstone therapy. 1, 2

Specific Topical Corticosteroid Regimens

• For widespread or difficult-to-reach lesions: Use betamethasone sodium phosphate 0.5 mg in 10 mL water, holding in mouth for 2-3 minutes before spitting out, 1-4 times daily 1, 2
• For localized, easily accessible ulcers: Apply clobetasol propionate 0.05% gel or ointment directly to affected areas, or mix in equal amounts with Orabase for better adherence 3, 2, 4
• Topical corticosteroids achieve approximately 94% good-to-excellent clinical response rates and demonstrate predictable safety and efficacy 2, 5

Adjunctive Symptomatic Management

• For pain control: Benzydamine hydrochloride oral rinse or spray every 3 hours, especially before eating 1, 2, 6
• For severe pain: Viscous lidocaine 2% applied up to 3-4 times daily 2, 6
• For oral hygiene: 0.2% chlorhexidine digluconate mouthwash 10 mL twice daily (can be diluted by 50% to reduce stinging) 1, 2
• For bacterial colonization: Warm saline mouthwashes daily 1, 2

Second-Line Treatment for Refractory Cases

When topical corticosteroids fail after 2 weeks of appropriate use, escalate to topical calcineurin inhibitors 6:

• Tacrolimus 0.1% ointment applied twice daily for 4 weeks is the preferred second-line agent 1, 2, 7
• Tacrolimus demonstrated superior improvement in OLP signs and symptoms compared to anti-inflammatory mouthwash at 3-month follow-up 7
• Pimecrolimus 1% is an alternative topical calcineurin inhibitor 4, 8

Important Caveat About Calcineurin Inhibitors

Topical calcineurin inhibitors show the highest incidence of adverse effects (RR 3.25,95% CI: 1.19-8.86) compared to other topical agents, which limits their routine first-line use despite efficacy 5, 9

Third-Line Treatment: Intralesional and Systemic Therapy

For highly symptomatic, recurrent, or non-resolving ulcers despite topical therapy 3, 1:

• Intralesional triamcinolone (weekly injections, total dose 28 mg) combined with topical clobetasol 0.05% 3, 1, 2
• Systemic corticosteroids: Prednisone/prednisolone 30-60 mg (or 1 mg/kg) daily for 1 week, followed by dose tapering over the second week 3, 1, 6

Alternative and Emerging Therapies

Recent network meta-analyses have identified promising alternatives 5, 9:

• Purslane ranked first in improving clinical symptoms (RR 4.53,95% CI: 1.45-14.11) and showed superior clinical resolution rates (OR 18.4,95% CI: 3.5-97) 5, 9
• Aloe vera demonstrated significant clinical improvement (RR 1.53,95% CI: 1.05-2.24) and pain resolution (OR 13,95% CI: 1.5-111.8) 5, 9
• Photodynamic therapy showed statistically significant improvement in clinical scores (MD -5.91,95% CI: -8.15, -3.68) 5
• Hyaluronic acid showed significant pain resolution (OR 24.8,95% CI: 1.3-457.6) 9

Critical Diagnostic Pitfall: Exclude Oral Herpes

Never use topical corticosteroids if oral herpes simplex virus infection is suspected, as corticosteroids potentiate HSV infection. 6

• Oral herpes presents with vesicles that rupture into ulcers, often with prodromal tingling and possible systemic symptoms 6
• If HSV is suspected, initiate antiviral treatment immediately (acyclovir 200-400 mg five times daily, valacyclovir 500 mg 2-3 times daily, or famciclovir 250 mg twice daily) 6
• Confirm OLP diagnosis with biopsy showing characteristic histopathology before starting corticosteroids 10, 11

Management of Secondary Candidal Infection

Corticosteroid use increases risk of candidiasis; treat infection first or concurrently 1:

• Nystatin oral suspension 100,000 units four times daily for 1 week 1, 2
• Miconazole oral gel 5-10 mL held in mouth after food four times daily for 1 week 1, 2

Long-Term Monitoring

OLP is considered an oral potentially malignant disorder with a pooled malignant transformation rate of 1.43% for OLP and 5.13% for OLP with dysplasia 11. Regular follow-up is essential to monitor for malignant transformation to squamous cell carcinoma 12, 11.